Turning Point Therapeutics, Inc.

NasdaqGS:TPTX Stock Report

Market Cap: US$3.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Turning Point Therapeutics Management

Management criteria checks 1/4

Turning Point Therapeutics' CEO is Athena Countouriotis, appointed in Sep 2018, has a tenure of 3.92 years. total yearly compensation is $16.94M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $8.39M. The average tenure of the management team and the board of directors is 2.3 years and 2 years respectively.

Key information

Athena Countouriotis

Chief executive officer

US$16.9m

Total compensation

CEO salary percentage3.84%
CEO tenure3.9yrs
CEO ownership0.2%
Management average tenure2.3yrs
Board average tenure2yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 21

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Bristol Myers  Squibb (NYSE:BMY) is reportedly expected to make antitrust filings to U.S. and German authorities "imminently" for its planned $4.1 billion purchase of Turning Point Therapeutics (NASDAQ:TPTX), according to a Dealreporter item. The acquisition remains on track for a Q3 closing, according to the report, which cited sources familiar. The deal update comes after BMY on Tuesday extended the tender offer for its acquisition of Turning Point Therapeutics (TPTX) to Aug. 15. BMY agreed to acquire the clinical-stage precision oncology biotech Turning Point (TPTX) at a price of $76.00 per share in cash for a total consideration of $4.1B early last month.
Analysis Article • Mar 23

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 06

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 03

The Take On Turning Point Therapeutics

After peaking at over $141 in February 2021, shares of Turning Point Therapeutics, Inc. had lost 55% of their value through early October, largely due to a data vacuum. That silence was broken on October 7, 2021, with solid, yet short-of-expectations results for its lead candidate (repotrectinib) in a second-line or later setting for ROS1+ NSCLC. The Street is still awaiting pivotal additional data for repotrectinib in a frontline setting, where initial data indicated a 90+% ORR for ROS1+ NSCLC. With a potentially best-in-class therapy and $1 billion in cash, this precision oncology firm merited a deeper dive. A full analysis follows in the paragraphs below.
Analysis Article • Aug 15

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Celebrations may be in order for Turning Point Therapeutics, Inc. ( NASDAQ:TPTX ) shareholders, with the analysts...
Analysis Article • Aug 04

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • May 08

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

It's been a mediocre week for Turning Point Therapeutics, Inc. ( NASDAQ:TPTX ) shareholders, with the stock dropping...
Analysis Article • Feb 26

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Analysis Article • Jan 22

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Celebrations may be in order for Turning Point Therapeutics, Inc. ( NASDAQ:TPTX ) shareholders, with the analysts...
Analysis Article • Jan 13

We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, Turning Point...
Analysis Article • Dec 15

Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Today we will run through one way of estimating the intrinsic value of Turning Point Therapeutics, Inc. ( NASDAQ:TPTX...

CEO Compensation Analysis

How has Athena Countouriotis's remuneration changed compared to Turning Point Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

-US$342m

Mar 31 2022n/an/a

-US$275m

Dec 31 2021US$17mUS$651k

-US$237m

Sep 30 2021n/an/a

-US$205m

Jun 30 2021n/an/a

-US$157m

Mar 31 2021n/an/a

-US$132m

Dec 31 2020US$15mUS$580k

-US$157m

Sep 30 2020n/an/a

-US$131m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$119m

Dec 31 2019US$3mUS$544k

-US$72m

Sep 30 2019n/an/a

-US$60m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$34m

Dec 31 2018US$9mUS$329k

-US$25m

Compensation vs Market: Athena's total compensation ($USD16.94M) is above average for companies of similar size in the US market ($USD6.59M).

Compensation vs Earnings: Athena's compensation has increased whilst the company is unprofitable.

CEO

Athena Countouriotis (50 yo)

3.9yrs
Tenure
US$16,940,858
Compensation

Dr. Athena Maria Countouriotis, M.D. is Chief Executive Officer and Director at Turning Point Therapeutics, Inc. since September 2018. She has been Independent Director of Passage Bio, Inc since February 2...

Leadership Team

NamePositionTenureCompensationOwnership
Athena Countouriotis
President3.9yrsUS$16.94m0.22%
$ 8.4m
Paolo Tombesi
Executive VP & CFO1.1yrsUS$4.58m0.057%
$ 2.2m
Mohammad Hirmand
Executive VP & Chief Medical Officer2.7yrsUS$5.61m0.082%
$ 3.1m
Ed Gemo
Senior VP & Chief Information Officerno datano datano data
Gavin Hirst
Senior VP of Chemistry & Interim Chief Scientific Officerno datano datano data
Adam Levy
Senior Vice President of Investor Relations & Corporate Communicationsless than a yearno datano data
Raymond Furey
Senior VP & Chief Compliance Officerno datano datano data
Brian Sun
Senior VPless than a yearno datano data
Heather Adams
Senior Vice President of Human Resources2.1yrsno datano data
Jeffrey Whitten
Senior Vice President of Pre-Clinical Developmentno datano datano data
Xiaohua Xin
Senior Vice President of Clinical Development3.6yrsno datano data
Homa Yeganegi
Senior VP2.6yrsno datano data
2.3yrs
Average Tenure
52yo
Average Age

Experienced Management: TPTX's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Athena Countouriotis
President3.9yrsUS$16.94m0.22%
$ 8.4m
Kevan Shokat
Chairman of Scientific Advisory Board2yrsno datano data
C. Machado
Independent Director3.3yrsUS$424.79k0%
$ 0
Carol Gallagher
Independent Director3.1yrsUS$415.29k0%
$ 0
Benjamin Cravatt
Member of Scientific Advisory Board2yrsno data0%
$ 0
Garry Nicholson
Independent Director2.6yrsUS$422.74k0%
$ 0
Simeon George
Independent Non-Executive Director5.3yrsUS$414.41k0%
$ 0
Mark J. Alles
Independent Chairman of the Board1.3yrsUS$861.18k0.0040%
$ 151.9k
Barbara Bodem
Independent Director1.4yrsUS$1.00mno data
Daniel Von Hoff
Member of Scientific Advisory Boardno datano datano data
Natalia Jura
Member of the Scientific Advisory Board2yrsno datano data
Michael Varney
Member of the Scientific Advisory Board2yrsno datano data
2.0yrs
Average Tenure
55.5yo
Average Age

Experienced Board: TPTX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/08/17 19:39
End of Day Share Price 2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Turning Point Therapeutics, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Arlinda LeeCanaccord Genuity
Silvan TuerkcanCitizens JMP Securities, LLC